Table 2.
Within-group mean changes from baseline (from day zero to the end of the intervention) for clinical markers.
| Variable | Control Intra-Group ∆ Change (SD) |
Intervention Intra-Group Δ Change (SD) |
Intervention Effect between Groups p-Value |
|---|---|---|---|
| HbA1c (%) | −0.044 (−0.164; 0.076) | 0.043 (−0.082; 0.169) | 0.087 (−0.086; 0.261) |
| Total cholesterol (mmol/L) | −0.024 (−0.167; 0.119) | −0.209 (−0.358; −0.059) | −0.185 (−0.392; 0.022) |
| Triglyceride (mmol/L) | −0.006 (−0.102; 0.090) | 0.004 (−0.096; 0.105) | 0.010 (−0.128; 0.149) |
| HDL (mmol/L) | 0.032 (−0.060; 0.123) | −0.077 (−0.173; 0.018) | −0.109 (−0.241; 0.023) |
| LDL (mmol/L) | 0.055 (−0.125; 0.235) | −0.171 (−0.358; 0.016) | −0.226 (−0.485; 0.034) |
| Total SF-36 (score) | −2.23 (−44.45; 47.29) | 28.34 (17.45; 37.59) | 30.66 (12.45; 48.23) |
| SF-36 mental health | −0.04 (−3.83; 6.75) | 5.60 (1.24; 7.96) | 5.64 (0.57; 10.70) |
| Glycemia (mg/dL) | 6.71 (−2.51; 15.94) | −7.06 (−17.70; 3.57) | −13.77 (−28.73; 1.18) |
| BMI (kg/m2) | −0.50 (−2.00; 1.01) | 0.53 (−0.25; 0.81) | −0.03 (−0.39; 0.33) |
In bold: value with p < 0.05. Abbreviations: HbA1c, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SF-36, Short Form 36.